Previous studies indicated that supplementation with SCFAs effectively decreased the expressing level of peroxisome proliferator-activated receptor gamma (PPARγ) in mice, achieved the transformation from lipid synthesis to lipid oxidation, and alleviated the metabolic disorders induced by HFD [59]. This evidence concerns the gene PPARG and Other metabolic disease.